查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083990

前列腺癌治療市場：依治療機制、治療階段、劑型、通路和最終用戶分類－2026-2032年全球市場預測

Prostate Cancer Therapeutics Market by Therapeutic Mechanism, Therapy Line, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，前列腺癌治療市場將成長至 175.9 億美元，複合年成長率為 6.64%。

主要市場統計數據
基準年 2025 112.1億美元
預計年份：2026年 118.4億美元
預測年份 2032 175.9億美元
複合年成長率 (%) 6.64%

前列腺癌的治療正從以傳統荷爾蒙療法為中心的模式轉向精準癌症治療模式，該模式結合了雄激素剝奪療法、雄激素受體通路抑製劑、紫杉烷類藥物、PARP抑製劑、PSMA靶向放射性藥物、針對特定生物標記患者的免疫療法以及骨靶向支持治療。臨床需求依然十分旺盛。根據GLOBOCAN 2022的預測，全球將新增超過146萬例攝護腺癌病例，約39.7萬人死亡，使攝護腺癌成為男性最常見的癌症之一。

市場發展勢頭正受到早期治療的改進、基因組檢測準確性的提高、PSMA-PET成像技術的廣泛應用以及轉移性激素敏感性前列腺癌、非轉移性去勢抗性前列腺癌和轉移性去勢抗性前列腺癌各階段療法的廣泛應用所推動。對於相關人員，競爭的前沿日益取決於生存獲益、耐受性、治療順序、真實世界臨床結果、診斷基礎設施以及支付方對高價值創新療法的信心等方面的證據。

前列腺癌治療前景的變革性變化

隨著先進療法被引入早期治療方案，前列腺癌的治療模式正在重塑。雄性激素受體路徑抑制劑在轉移性荷爾蒙敏感性前列腺癌的應用，徹底改變了標準治療方案。同時，非轉移性去勢抗性前列腺癌已成為旨在延緩轉移和延長存活期的重要治療標靶。

人工智慧對前列腺癌治療的累積影響

在治療攝護腺癌整體，人工智慧（AI）正逐漸成為累積的驅動力，而非一次性的改變。在藥物發現和轉化研究中，AI 分析基因組、影像、病理和臨床資料集，以支持標靶優先排序、分子模式識別和臨床試驗候選藥物篩選。這些功能使研發人員能夠識別出對治療有反應的患者亞群，從而降低因樣本量不足或候選藥物選擇不當而導致的臨床試驗風險。

關鍵區域洞察：全球採用趨勢

在亞太地區，隨著中國、日本、韓國、印度和澳洲加強腫瘤基礎設施建設、擴大先進影像診斷的覆蓋範圍以及推廣新型荷爾蒙療法，市場正在不斷擴張。日本、韓國和澳洲受益於成熟的健保報銷體系和專科醫生網路；中國正在擴大癌症治療能力；印度儘管面臨經濟挑戰，但正透過大規模三級癌症治療中心改善醫療服務。北美地區憑藉著較高的疾病認知度、先進的診斷技術、學術臨床試驗網路以及放射性配體和生物標記靶向療法的法規核准，繼續保持其在創新和醫療保健報銷方面的領先地位。

關鍵群體分析：策略市場叢集

在東協市場，都市區腫瘤中心的重要性日益凸顯，因為它們能夠擴大荷爾蒙療法、影像檢查和專科護理的覆蓋範圍。然而，保險報銷機制的差異阻礙了進行性前列腺癌治療的持續推廣。海灣合作理事會（GCC）成員國預計將透過投資專科醫院、核醫基礎設施和數位醫療項目，以及製定支持早期診斷和強化癌症治療的國家癌症策略，加快相關治療的推廣。

重點國家洞察：首選前列腺癌市場

美國在前列腺癌治療領域處於全球創新前沿，美國癌症協會預測，到2024年，美國將新增約299,010例前列腺癌病例，並有35,250人死亡。這得歸功於臨床試驗、先進的影像技術、基因組檢測以及廣泛的專科癌症護理服務。加拿大受益於完善的癌症護理體系和精準腫瘤學的日益普及，而墨西哥和巴西則面臨著公立和私立醫療體系之間服務獲取不均以及對大城市癌症中心日益成長的依賴所帶來的日益成長的需求。

為行業領導者提供的實用建議

產業領導者應優先考慮提供證據，證明在明確界定的列腺癌患者群體中，該療法能夠改善總體生存期、影像學無惡化生存期、提高生活品質、增強安全性並體現真實世界的臨床價值。將伴隨診斷、PSMA成像路徑和基因組檢測支援整合到商業化計劃中的機構，將更有利於掌握生物標記主導的市場需求。

調查方法

本執行摘要綜合運用了公開的流行病學、監管、臨床和市場進入資訊來源。主要參考資料包括全球癌症負擔估計、國家癌症統計數據、法規核准情況、臨床指南趨勢、同行評審的臨床試驗證據、腫瘤基礎設施指標以及公開的醫療保健系統資訊。

結論

前列腺癌治療領域正步入一個新時代，其特點是精準治療、早期治療的強化、PSMA靶向放射性配體的創新以及數據驅動的醫療服務。儘管目前先進藥物的引進主要由高所得市場主導，但從長遠來看，最大的機會將來自於新興地區診斷、基因組檢測和影像技術的可及性提升，以及治療費用的可負擔性和治療的連續性提高。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 前列腺癌藥物市場：依治療機制分類

  • 化療
    • 含鉑類藥物
    • 紫杉烷類藥物
  • 荷爾蒙療法
    • 抗雄激素
    • CYP17抑制劑
    • GnRH促效劑
    • GnRH拮抗劑
  • 免疫療法
    • 癌症疫苗
    • 細胞療法
    • 查核點抑制劑
  • 放射性藥物
    • α粒子發射材料
    • BETA射線放射體
  • 標靶治療
    • 單株抗體
    • PARP抑制劑
    • 蛋白酪氨酸激酶抑制劑

第8章：前列腺癌藥物市場：依治療方案分類

  • 一線治療
  • 第二行
  • 從第三行開始

第9章：攝護腺癌治療市場：依劑型分類

  • 注射藥物
  • 口服

第10章 攝護腺癌治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 攝護腺癌治療藥物市場：依最終用戶分類

  • 癌症中心
  • 居家照護提供者
  • 醫院
  • 專科診所

第12章 攝護腺癌治療藥物市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 攝護腺癌治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 前列腺癌治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Ipsen SA
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4342CA3266BF

The Prostate Cancer Therapeutics Market is projected to grow by USD 17.59 billion at a CAGR of 6.64% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.21 billion
Estimated Year [2026] USD 11.84 billion
Forecast Year [2032] USD 17.59 billion
CAGR (%) 6.64%

Prostate cancer therapeutics are moving from a historically hormone-centered category toward a precision oncology model that combines androgen deprivation therapy, androgen receptor pathway inhibitors, taxanes, PARP inhibitors, PSMA-targeted radiopharmaceuticals, immunotherapy for selected biomarker-defined patients, and supportive bone-targeted care. The clinical need remains substantial: GLOBOCAN 2022 estimated more than 1.46 million new prostate cancer cases and approximately 397,000 deaths worldwide, making prostate cancer one of the most frequently diagnosed cancers in men.

Market momentum is being shaped by earlier treatment intensification, improved genomic testing, expanded PSMA PET imaging, and broader use of therapies across metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer. For industry stakeholders, the competitive frontier is increasingly defined by survival benefit, tolerability, sequencing evidence, real-world outcomes, diagnostic infrastructure, and payer confidence in high-value innovation.

Transformative Shifts in the Prostate Cancer Treatment Landscape

The prostate cancer treatment landscape is being reshaped by the migration of advanced therapies into earlier lines of care. Treatment intensification with androgen receptor pathway inhibitors in metastatic hormone-sensitive disease has changed standard practice, while non-metastatic castration-resistant prostate cancer has become a key setting for delaying metastasis and extending survival.

Precision medicine is another defining shift. Regulatory approvals for PARP inhibitors in selected patients with homologous recombination repair alterations and PSMA-targeted radioligand therapy for eligible metastatic castration-resistant disease have established biomarker-enabled treatment as a major clinical and commercial driver. At the same time, demand for PSMA PET imaging, next-generation sequencing, liquid biopsy, and multidisciplinary treatment pathways is increasing the strategic value of diagnostics partnerships and integrated care models.

Cumulative Impact of Artificial Intelligence in Prostate Cancer Therapeutics

Artificial intelligence is becoming a cumulative enabler across prostate cancer therapeutics, not a single-point disruption. In discovery and translational research, AI supports target prioritization, molecular pattern recognition, and trial enrichment by analyzing genomic, imaging, pathology, and clinical datasets. These capabilities can help developers identify responsive subpopulations and reduce the risk of underpowered or poorly selected trials.

In clinical practice, AI-assisted pathology and radiology may improve risk stratification, lesion detection, and treatment planning when validated against rigorous clinical standards. In commercialization, AI-driven real-world evidence analytics can help manufacturers understand treatment sequencing, adherence, toxicity patterns, and health equity gaps. The strongest opportunity lies in responsibly governed AI systems that improve decision support while protecting patient privacy, reducing bias, and aligning with regulatory expectations.

Key Regional Insights: Global Adoption Patterns

Asia-Pacific is expanding as China, Japan, South Korea, India, and Australia strengthen oncology infrastructure, broaden access to advanced imaging, and increase adoption of novel hormonal agents. Japan, South Korea, and Australia benefit from mature reimbursement and specialist networks, while China is scaling cancer care capacity and India is improving access through large tertiary oncology centers despite affordability constraints. North America remains a leading innovation and reimbursement region, supported by high disease awareness, advanced diagnostics, academic trial networks, and regulatory approvals for radioligand and biomarker-directed therapies.

Latin America shows growing demand but uneven access, with Brazil and Mexico acting as important treatment hubs while reimbursement constraints and fragmented health coverage influence uptake of premium therapies. Europe benefits from strong guideline adoption, cancer registries, multidisciplinary urology-oncology care, and expanding PSMA PET and genomic testing capabilities, although pricing, procurement, and health technology assessment requirements vary by country.

The Middle East, led by Gulf health system investment, is increasing access to oncology centers, nuclear medicine capacity, and specialty care for advanced prostate cancer. Africa continues to face underdiagnosis, late presentation, and limited access to advanced therapeutics in many markets, making diagnostic capacity, workforce training, pathology services, radiotherapy availability, and affordable treatment pathways essential to long-term development.

Key Group Insights: Strategic Market Clusters

ASEAN markets are gaining relevance as urban oncology centers expand access to hormonal therapies, imaging, and specialist care, though reimbursement variation remains a barrier to consistent adoption of advanced prostate cancer therapeutics. The GCC is positioned for faster uptake due to investment in specialty hospitals, nuclear medicine infrastructure, digital health programs, and national cancer strategies that support earlier diagnosis and centralized cancer care.

The European Union remains central to evidence-based adoption because centralized regulatory review is followed by country-level health technology assessment, reimbursement decisions, and pricing negotiations. BRICS countries represent a significant treatment-access opportunity, combining large patient populations with policy efforts to localize manufacturing, expand cancer services, strengthen screening awareness, and improve availability of innovative oncology medicines.

G7 countries continue to influence clinical guidelines, pricing benchmarks, regulatory standards, real-world evidence expectations, and adoption of precision oncology tools such as genomic testing and PSMA PET imaging. NATO members overlap substantially with North American and European high-income markets, where supply chain resilience, radiopharmaceutical logistics, isotope access, cybersecurity, and secure health data infrastructure are becoming increasingly relevant to oncology care continuity.

Key Country Insights: Priority Prostate Cancer Markets

The United States anchors global prostate cancer therapeutics innovation, with the American Cancer Society estimating about 299,010 new prostate cancer cases and 35,250 deaths in 2024, supported by broad access to clinical trials, advanced imaging, genomic testing, and specialty oncology care. Canada benefits from organized cancer systems and growing precision oncology adoption, while Mexico and Brazil show rising demand amid unequal access across public and private health systems and increasing reliance on major urban oncology centers.

The United Kingdom, Germany, France, Italy, and Spain are influential European markets shaped by guideline-driven care, national reimbursement decisions, multidisciplinary cancer networks, and expanding use of advanced diagnostics. Germany and France maintain strong oncology infrastructure, the United Kingdom emphasizes evidence-based access through national assessment pathways, and Italy and Spain continue to advance specialist care delivery across regional health systems. Russia remains a sizable market by population but faces access, reimbursement, and supply considerations that influence adoption of newer prostate cancer agents.

China is scaling oncology access, genomic medicine, nuclear medicine capacity, and domestic innovation, while India has high long-term treatment need but significant affordability and access constraints outside leading metropolitan cancer centers. Japan maintains strong adoption of advanced therapies under a structured reimbursement system, Australia offers mature cancer care and active clinical trial participation, and South Korea combines advanced diagnostics, digital health capability, and a competitive biopharmaceutical ecosystem to support precision prostate cancer treatment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that demonstrates overall survival, radiographic progression-free survival, quality of life, safety, and real-world value across clearly defined prostate cancer patient segments. Organizations that integrate companion diagnostics, PSMA imaging pathways, and genomic testing support into commercialization plans will be better positioned to capture biomarker-driven demand.

Strategic focus should also include treatment sequencing research, radiopharmaceutical supply chain resilience, isotope availability planning, referral pathway optimization, and differentiated patient support programs. In cost-sensitive markets, tiered access models, local partnerships, physician education, and health economic evidence will be critical for sustainable growth in prostate cancer therapeutics.

Research Methodology

This executive summary is developed through triangulation of publicly available epidemiology, regulatory, clinical, and market-access sources. Core references include global cancer burden estimates, national cancer statistics, regulatory approvals, clinical guideline trends, peer-reviewed trial evidence, oncology infrastructure indicators, and publicly available health system information.

The analysis emphasizes verified disease burden, approved therapeutic classes, observable adoption drivers, documented infrastructure trends, and evidence-based access considerations. Insights are synthesized to support strategic decision-making across pharmaceutical development, diagnostics integration, regional access planning, and competitive positioning in prostate cancer therapeutics, while avoiding market sizing, market share estimation, and forecasting.

Conclusion

The prostate cancer therapeutics category is entering a new era defined by precision treatment, earlier intensification, PSMA-targeted radioligand innovation, and data-enabled care delivery. While high-income markets lead adoption of advanced agents, the largest long-term opportunities will come from improving diagnosis, genomic testing, imaging access, affordability, and treatment continuity across emerging regions.

Organizations that combine differentiated clinical evidence with diagnostic integration, AI-enabled real-world insights, radiopharmaceutical readiness, and regionally tailored access strategies will be best positioned to compete in this evolving oncology category.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Prostate Cancer Therapeutics Market, by Therapeutic Mechanism

  • 7.1. Chemotherapy
    • 7.1.1. Platinum Compounds
    • 7.1.2. Taxanes
  • 7.2. Hormone Therapy
    • 7.2.1. Antiandrogens
    • 7.2.2. CYP17 Inhibitors
    • 7.2.3. GnRH Agonists
    • 7.2.4. GnRH Antagonists
  • 7.3. Immunotherapy
    • 7.3.1. Cancer Vaccines
    • 7.3.2. Cell Therapy
    • 7.3.3. Checkpoint Inhibitors
  • 7.4. Radiopharmaceuticals
    • 7.4.1. Alpha Emitters
    • 7.4.2. Beta Emitters
  • 7.5. Targeted Therapy
    • 7.5.1. Monoclonal Antibodies
    • 7.5.2. Parp Inhibitors
    • 7.5.3. Tyrosine Kinase Inhibitors

8. Prostate Cancer Therapeutics Market, by Therapy Line

  • 8.1. First Line
  • 8.2. Second Line
  • 8.3. Third Line & Beyond

9. Prostate Cancer Therapeutics Market, by Formulation

  • 9.1. Injectable
  • 9.2. Oral

10. Prostate Cancer Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Prostate Cancer Therapeutics Market, by End User

  • 11.1. Cancer Centers
  • 11.2. Homecare Providers
  • 11.3. Hospitals
  • 11.4. Specialty Clinics

12. Prostate Cancer Therapeutics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Prostate Cancer Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Prostate Cancer Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. AbbVie Inc.
  • 16.2. Amgen Inc.
  • 16.3. Astellas Pharma Inc.
  • 16.4. AstraZeneca PLC
  • 16.5. Bayer AG
  • 16.6. Bristol-Myers Squibb Company
  • 16.7. Eisai Inc.
  • 16.8. Eli Lilly and Company
  • 16.9. F. Hoffmann-La Roche AG
  • 16.10. Genentech, Inc.
  • 16.11. GlaxoSmithKline plc
  • 16.12. Ipsen S.A.
  • 16.13. Johnson & Johnson Services Inc.
  • 16.14. Merck & Co., Inc.
  • 16.15. Novartis AG
  • 16.16. Pfizer Inc.
  • 16.17. Sanofi S.A.
  • 16.18. Takeda Pharmaceutical Company Limited
  • 16.19. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PLATINUM COMPOUNDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PLATINUM COMPOUNDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PLATINUM COMPOUNDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TAXANES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TAXANES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TAXANES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HORMONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HORMONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIANDROGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIANDROGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIANDROGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CYP17 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CYP17 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CYP17 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GNRH AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GNRH AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GNRH AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GNRH ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BETA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BETA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PARP INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PARP INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PARP INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOMECARE PROVIDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOMECARE PROVIDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOMECARE PROVIDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 185. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 187. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 214. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 219. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 225. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 229. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 231. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 232. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 263. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. MEXICO PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 274. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 296. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 307. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 309. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 310. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 312. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 314. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 315. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 318. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 319. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 321. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 322. RUSSIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 326. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 327. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 328. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 329. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 330. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 331. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 332. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MECHANISM, 2018-2032 (USD MILLION)
  • TABLE 336. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 337. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, BY HORMONE THERAPY, 2018-2032 (USD MILLION)

TABLE 338